DNA methylation profiles of long- and short-term glioblastoma survivors

Epigenetics

Volumn 8, Issue 2, 2013, Pages 149-156

  Shinawi, Thoraia ^a   Hill, Victoria K ^a   Krex, Dietmar ^b   Schackert, Gabriele ^b   Gentle, Dean ^a   Morris, Mark R ^c   Wei, Wenbin ^d   Cruickshank, Garth ^d   Maher, Eamonn R ^a   Latif, Farida ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^c UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

DNA methylation; Gliomas; IDH1; Long term survivors; Short term survivors

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; RAB PROTEIN; TRANSCRIPTION FACTOR PDX 1;

ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE MUTATION; GENETIC ASSOCIATION; GLIOBLASTOMA; HUMAN; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84874363487     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.23398     Document Type: Article

References (15)

1. Krex D, Klink B, Hartmann C, von Deimling A, Pietsch T, Simon M, et al.; German Glioma Network. Long-term survival with glioblastoma multiforme. Brain 2007; 130:2596-606; PMID:17785346; http:// dx.doi.org/10.1093/brain/awm204.
2. Hesson LB, Krex D, Latif F. Epigenetic markers in human gliomas: prospects for therapeutic intervention. Expert Rev Neurother 2008; 8:1475-96; PMID:18928342; http://dx.doi.org/10.1586/14737175.8.10.1475.
3. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, et al.; Cancer Genome Atlas Research Network. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010; 17:510-22; PMID:20399149; http://dx.doi.org/10.1016/j. ccr.2010.03.017.
4. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012; 483:479-83; PMID:22343889; http://dx.doi. org/10.1038/nature10866.
5. Dallol A, Krex D, Hesson L, Eng C, Maher ER, Latif F. Frequent epigenetic inactivation of the SLIT2 gene in gliomas. Oncogene 2003; 22:4611-6; PMID:12881718; http://dx.doi.org/10.1038/ sj.onc.1206687.
6. Hesson L, Bièche I, Krex D, Criniere E, Hoang-Xuan K, Maher ER, et al. Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas. Oncogene 2004; 23:2408-19; PMID:14743209; http://dx.doi.org/10.1038/ sj.onc.1207407.
7. Martinez R, Martin-Subero JI, Rohde V, Kirsch M, Alaminos M, Fernandez AF, et al. A microarray-based DNA methylation study of glioblastoma multiforme. Epigenetics 2009; 4:255-64; PMID:19550145.
8. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics 2011; 6:692-702; PMID:21593595; http://dx.doi.org/10.4161/ epi.6.6.16196.
9. Cahill N, Bergh AC, Kanduri M, Göransson-Kultima H, Mansouri L, Isaksson A, et al. 450K-array analysis of chronic lymphocytic leukemia cells reveals global DNA methylation to be relatively stable over time and similar in resting and proliferative compartments. Leukemia 2012; 27:150-8; PMID:22922567; http:// dx.doi.org/10.1038/leu.2012.245.
10. Roessler J, Ammerpohl O, Gutwein J, Hasemeier B, Anwar SL, Kreipe H, et al. Quantitative crossvalidation and content analysis of the 450k DNA methylation array from Illumina, Inc. BMC Res Notes 2012; 5:210; PMID:22546179; http://dx.doi. org/10.1186/1756-0500-5-210.
11. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008; 24:1547-8; PMID:18467348; http://dx.doi. org/10.1093/bioinformatics/btn224.
12. Hill VK, Hesson LB, Dansranjavin T, Dallol A, Bieche I, Vacher S, et al. Identification of 5 novel genes methylated in breast and other epithelial cancers. Mol Cancer 2010; 9:51; PMID:20205715; http://dx.doi. org/10.1186/1476-4598-9-51.
13. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350-4; PMID:11070098; http://dx.doi. org/10.1056/NEJM200011093431901.
14. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009; 118:469-74; PMID:19554337; http://dx.doi.org/10.1007/s00401-009-0561-9.
15. Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, et al. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 2011; 30:978-89; PMID:20956940; http:// dx.doi.org/10.1038/onc.2010.471.